-

06:28:00 AM

MDWD Stock News

MDWD - MediWound Ltd

05/17/22 7:01 AM

Nasdaq : MDWD

low float

MediWound Announces CEO Transition

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated

RHEA-AI

very positive

05/17/22 7:00 AM

Nasdaq : MDWD

earningslow float

MediWound Reports First Quarter 2022 Financial Results

MediWound Ltd. (NASDAQ: MDWD), a fully-integrated

RHEA-AI

neutral

05/12/22 7:00 AM

Nasdaq : MDWD

clinical triallow float

MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds

Study Met Primary and Key Secondary Endpoints with Statistically Significant Results Compared to Control Arms Significant Improvement Across Multiple Measures Over the Current Non-Surgical Standard-of Care No Deleterious Effect on Wound Closure and No Observed Safety Issues End of Phase 2 Meeting

RHEA-AI

neutral

05/10/22 4:01 PM

Nasdaq : MDWD

conferencesearningslow float

MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022

MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first

RHEA-AI

neutral

04/12/22 8:00 AM

Nasdaq : MDWD

low float

MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company

RHEA-AI

positive

03/29/22 8:00 AM

Nasdaq : MDWD

conferencesclinical triallow float

MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic

RHEA-AI

positive

03/22/22 4:05 PM

Nasdaq : MDWD

low float

MediWound Announces Exercise of Over-Allotment Option

MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that the underwriter of

RHEA-AI

neutral

03/21/22 7:30 AM

Nasdaq : MDWD

clinical triallow float

MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic

RHEA-AI

neutral

03/17/22 7:00 AM

Nasdaq : MDWD

earningslow float

MediWound Reports Fourth Quarter and Full Year 2021 Financial Results

Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022 Raised Gross Proceeds of $10 Million through Public Equity Offering Conference Call Begins Today at 8:30 am ET

RHEA-AI

neutral

03/10/22 5:05 PM

Nasdaq : MDWD

offeringlow float

MediWound Announces Closing of Public Offering of Ordinary Shares

MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that on March 7, 2022 it

RHEA-AI

neutral

1 2 3 4 5 6 Next